<DOC>
	<DOCNO>NCT00002382</DOCNO>
	<brief_summary>To offer investigational agent ( saquinavir ) people HIV/AIDS need additional treatment option eligible enroll ongoing clinical trial . Patients longer benefit exist antiretroviral therapy currently enrol ongoing saquinavir trial eligible compassionate treatment program .</brief_summary>
	<brief_title>A Study Saquinavir Used Alone Combination With Other Anti-HIV Drugs HIV-Infected Patients</brief_title>
	<detailed_description>Patients longer benefit exist antiretroviral therapy currently enrol ongoing saquinavir trial eligible compassionate treatment program . Patients may register program physician , responsible supervise administration treatment ; follow guideline saquinavir dose interruption , dose reduction , discontinuation ; assess patient progress throughout duration study . Access saquinavir determine lottery system ; 60 percent program slot reserve patient CD4 count 50 less remain 40 percent slot devote patient CD4 count 51 300 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : Seropositivity HIV 1 antibody ELISA test , confirmation alternative method . CD4 count &lt; = 300 cells/mm3 ( within 4 week prior entry ) . Signed , inform consent parent legal guardian patient &lt; 18 year age . Failed previous therapy intolerant register antiretroviral drug . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Eligibility control clinical study experimental HIV therapy . Grade 4 hematologic and/or Grade 3 hematologic toxicity baseline . Patients follow prior condition exclude : Known hypersensitivity saquinavir protease inhibitor . 1 . Drugs , rifampin rifabutin , induce hepatic enzyme likely result decrease level saquinavir , therefore , avoid possible . Concomitant therapy treatment keep minimum . Current participation study formally exclude concomitant treatment experimental drug . 1 . Saquinavir use combination register antiretroviral drug ZDV , ddC and/or ddl . Other yet register antiretroviral drug use combination saquinavir drug widely available respective country allow combination treatment ongoing clinical study . Prophylactic treatment opportunistic infection .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1997</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Patient Selection</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>